Key result
NSAID treatment effectively lowered PGF2 alpha, PGE2, and TXB2 levels in joint fluid compared to untreated patients, though arthritis symptoms persisted despite lowered levels.
Why the study?
Does NSAID treatment reduce prostaglandin and thromboxane levels in the joint fluid of patients with rheumatoid arthritis?
Observational
Does NSAID treatment reduce prostaglandin and thromboxane levels in the joint fluid of patients with rheumatoid arthritis?
NSAIDs effectively reduce prostaglandin and thromboxane levels in rheumatoid arthritis joint fluid, but this biochemical reduction does not necessarily resolve clinical symptoms.
Answers are grounded in this paper and cite their sources.
NSAID-linked prostaglandin suppression in RA joint fluid may not relieve symptoms; leaves open whether these mediators primarily drive clinical arthritis.
Prostaglandin F2 alpha (PGF2 alpha), prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) levels were determined by radioimmunoassay (RIA) in knee joint fluid in two groups of patients with classical or definite rheumatoid arthritis (RA). One group had no treatment for one week prior to the study. The second group consisted of patients who developed acute exudative arthritis despite the use of various non-steroidal anti-inflammatory drugs (NSAID). The main metabolites of PGF2 alpha in plasma and urine were measured in the untreated group. The conclusion to be drawn from this study are: 1) Treatment with NSAID effectively lowers PGF2 alpha and PGE2 and TXB2 levels in joint fluid. 2) Signs and symptoms of arthritis may persist in spite of lowered levels of PGF2 alpha and PGE2 in the joint fluid. 3) The main metabolites of PGF2 alpha in plasma and urine are above the low-normal limit in untreated patients. 4) The ratio TXB2/PG was low in untreated patients, suggesting that the thromboxane pathway is quantitatively minor in rheumatoid joint inflammation.
No takes yet. Share an insight, caveat, or question.
Trang et al. (1977) conducted an observational in Rheumatoid Arthritis. NSAID treatment vs. No treatment for one week prior to the study was evaluated on Levels of PGF2 alpha, PGE2, and TXB2 in knee joint fluid. NSAID treatment effectively lowered PGF2 alpha, PGE2, and TXB2 levels in joint fluid compared to untreated patients, though arthritis symptoms persisted despite lowered levels.
Synapse has enriched 10 related papers. Consider them for comparative context: